Pancreatic Cancer Research

ResearcherAC Camargo HospitalActive in the last 2 years

Victor Hugo Fonseca de Jesus

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-4702-116X; OpenAlex author ID A5086610499. Sources: OpenAlex.

Their work

Papers
18 (first author 2, last author 5)
Trials
0
Grants
0
Labs led
2
Collaborators
16
Papers, trials and grants by year

2018: 3 papers · 2019: 1 paper · 2020: 1 paper · 2021: 2 papers · 2022: 2 papers · 2023: 3 papers · 2024: 3 papers · 2025: 2 papers · 2026: 1 paper

Papers 18

  1. Neoadjuvant therapy versus upfront surgery followed by adjuvant chemotherapy in resectable or borderline resectable PDAC: a systematic review and meta-analysis… Co-author DOI 10.1177/17588359261449077↗
  2. Pancreatic Ductal Adenocarcinoma with Medullary Features and a Complete Pathological Response After Neoadjuvant FOLFIRINOX: A Case Report and Literature Review. Last author DOI 10.1007/s12029-024-01140-5↗
  3. Stepped-wedge clinical trials in pancreatic cancer: a step backward in improving overall survival or a leap forward to enhance quality of care? First author DOI 10.21037/gs-24-472↗
  4. Current clinical practice in the management of Brazilian patients with potentially resectable pancreatic ductal adenocarcinoma (PDAC). Co-author DOI 10.1002/jso.27453↗
  5. A narrative review on rare types of pancreatic cancer: should they be treated as pancreatic ductal adenocarcinomas? Co-author DOI 10.1177/17588359241265213↗
  6. Incidence, risk factors and the prognostic role of thromboembolic events (TEEs) amongst patients with metastatic pancreatic adenocarcinoma (PAAD): a retrospect… Last author DOI 10.3332/ecancer.2024.1738↗
  7. Impact of Granulocyte Colony-Stimulating Factor (G-CSF) on the Outcomes of Patients With Metastatic Pancreatic Adenocarcinoma (MPA) During First-Line Treatment… Last author DOI 10.1177/10732748221149543↗
  8. Current Treatment of Potentially Resectable Pancreatic Ductal Adenocarcinoma: A Medical Oncologist's Perspective. Co-author DOI 10.1177/10732748231173212↗
  9. Targeting KRAS in Pancreatic Ductal Adenocarcinoma: The Long Road to Cure. Co-author DOI 10.3390/cancers15205015↗
  10. Patterns of disease relapse and posttreatment follow-up of patients with resected pancreatic adenocarcinoma: A single-center analysis. Last author DOI 10.1002/jso.26985↗
  11. Short-term survival of patients with advanced pancreatic cancer admitted to intensive care unit: a retrospective cohort study. Last author DOI 10.3332/ecancer.2022.1475↗
  12. Disparities in access to health care system as determinant of survival for patients with pancreatic cancer in the State of São Paulo, Brazil. Co-author DOI 10.1038/s41598-021-85759-5↗
  13. Comparative efficacy of modified FOLFIRINOX, gemcitabine plus capecitabine and gemcitabine plus nab-paclitaxel as adjuvant treatment for resected pancreatic ca… Co-author DOI 10.3332/ecancer.2021.1276↗
  14. Systematic review and meta-analysis of gemcitabine-based chemotherapy after FOLFIRINOX in advanced pancreatic cancer. Co-author DOI 10.1177/1758835920905408↗
  15. Characteristics and survival of older patients with metastatic pancreatic cancer: a retrospective analysis of the AC Camargo Cancer Center experience. First author DOI 10.1177/1758835919874650↗
  16. Role of staging laparoscopy in the management of Pancreatic Duct Carcinoma (PDAC): Single-center experience from a tertiary hospital in Brazil. Co-author DOI 10.1002/jso.25024↗
  17. Retrospective comparison of the efficacy and the toxicity of standard and modified FOLFIRINOX regimens in patients with metastatic pancreatic adenocarcinoma. Co-author DOI 10.21037/jgo.2018.04.02↗
  18. Retrospective analysis of efficacy and safety of Gemcitabine-based chemotherapy in patients with metastatic pancreatic adenocarcinoma experiencing disease prog… Co-author DOI 10.21037/jgo.2018.06.08↗

Closest collaborators

The 16 strongest of 16 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Rachel P. Riechelmann · 7 shared papers, 2020–2026 · strength 1.92
  2. Mauro Daniel Spina Donadio · 4 shared papers, 2018–2025 · strength 1.03
  3. Angelo Borsarelli Carvalho Brito · 2 shared papers, 2023–2024 · strength 0.62
  4. Renata D’Alpino Peixoto · 2 shared papers, 2023–2024 · strength 0.42
  5. Felipe José Fernández Coimbra · 3 shared papers, 2018–2022 · strength 0.40
  6. Arthur Conelian Gentili · 1 shared paper, 2024 · strength 0.31
  7. Cícero Gonzaga Santos · 1 shared paper, 2024 · strength 0.31
  8. Aldo Lourenço Abbade Dettino · 2 shared papers, 2019–2021 · strength 0.29
  9. Rodrigo Gomes Taboada · 1 shared paper, 2025 · strength 0.27
  10. Tiago Cordeiro Felismino · 1 shared paper, 2025 · strength 0.27
  11. Wilson Luiz da Costa · 2 shared papers, 2018–2021 · strength 0.23
  12. Marina Junqueira de Almeida · 1 shared paper, 2022 · strength 0.22
  13. Lucas Ferreira Sant’Ana · 2 shared papers, 2018 · strength 0.18
  14. Beatriz Alvarenga Gonzales · 1 shared paper, 2022 · strength 0.16
  15. María Paula Curado · 1 shared paper, 2021 · strength 0.15
  16. Josenon Gomes Costa · 1 shared paper, 2019 · strength 0.14

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.